Skye Bioscience, Inc. 8-K

What Happened
Skye Bioscience, Inc. (SKYE) filed an 8-K (Item 8.01) reporting that Nasdaq approved a transfer of the company's common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective with the open of business on June 23, 2026. This transfer follows the Company’s Form 10‑Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $9,011,804—below the Nasdaq Global Market minimum of $10,000,000. The Company’s ticker symbol, “SKYE,” remains unchanged.

Key Details

• Nasdaq approved the exchange tier transfer on June 18, 2026; effective June 23, 2026.
• Reported stockholders’ equity (Q1 2026): $9,011,804. Nasdaq Global Market minimum: $10,000,000; Nasdaq Capital Market minimum: $3,000,000.
• The Company previously received a notice (March 17, 2026) that its closing bid price had been below the $1.00 minimum for 30 consecutive business days; the initial compliance period to regain the minimum bid price runs through September 14, 2026 and continues after the transfer.
• The Company will monitor the closing bid price and consider options to regain compliance but stated there is no assurance it will do so.

Why It Matters
The tier transfer reflects that Skye Bioscience no longer met the higher stockholders’ equity standard for the Nasdaq Global Market but does meet the Capital Market listing threshold. For investors, the move can affect perceptions of the company’s size and regulatory requirements; continued low trading price remains a separate compliance risk with a deadline of September 14, 2026. The company’s trading symbol and ability to trade remain intact, but there is no guarantee it will regain compliance with Nasdaq’s minimum bid price or other listing standards.